跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,128 条关于
“Canadian CML Network”
全部
12,128
临床试验
7,472
药物
486
机构
236
资讯
3,934
9个月前
Ontario Launches FAST Program with Scemblix as First Priority Cancer Therapy for CML Patients
去年
Risk Management Strategies Improve Long-Term Safety Profile of Ponatinib in CML and ALL
去年
FDA Approves Nilotinib Tablets (Danziten) Without Mealtime Restrictions for CML
去年
FDA Approves Asciminib (Scemblix) for Newly Diagnosed Philadelphia Chromosome-Positive CML
去年
FDA Approves Danziten, a Nilotinib Formulation for CML Without Mealtime Restrictions
去年
FDA Approves Azurity's Danziten (Nilotinib) for CML Without Mealtime Restrictions
去年
Asciminib's Rising Prominence and Evolving Treatment Strategies in Chronic Myeloid Leukemia
去年
SOHO 2024: Advancements in ALL, CML, and CLL Treatment Strategies
去年
Apotex Launches First Generic Nilotinib in US with 180-Day Market Exclusivity
11个月前
Bayer Canada Partners with Mint Pharmaceuticals for ADALAT XL Distribution to Strengthen Canadian Market Access
第 1 页,共 394 页
上一页
下一页